Zemin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zemin Zhang has a total of 767 co-authors. Here are the top co-authors by number of shared publications:
- Guohui Dang
Changping Laboratory, Beijing, China
26 shared publications - Yuhui Miao
Changping Laboratory, Beijing, China
26 shared publications - Dan Tong
Changping Laboratory, Beijing, China
25 shared publications - Yu Zhang
Changping Laboratory, Beijing, China
25 shared publications - Xianwen Ren
Changping Laboratory, Beijing, China
23 shared publications - Liangtao Zheng
Analytical Biosciences Limited 6 , Beijing, China
22 shared publications
Latest Publications
- 1 July 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (8) , 1052-1054
Targeting SPP1 requires moving beyond ligand blockade
- 1 July 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (8) , 1052-1054
Targeting SPP1 requires moving beyond ligand blockade
- Open Access
- 24 June 2026
- Published by Elsevier in Trends in Cell Biology
- Vol. 36 (9) , 764-777
Multicellular ecosystems: Linking cellular diversity to tissue function and disease
- 24 June 2026
- Published by Elsevier in Trends in Cell Biology
- Vol. 36 (9) , 764-777
Open AccessMulticellular ecosystems: Linking cellular diversity to tissue function and disease
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1